Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

NCT00640328 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00640328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00640328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
October 31, 2011
Enrollment
38 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis